09R
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The compan… Read more
09R (09R) - Total Liabilities
Latest total liabilities as of September 2025: €8.49 Million EUR
Based on the latest financial reports, 09R (09R) has total liabilities worth €8.49 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
09R - Total Liabilities Trend (2021–2024)
This chart illustrates how 09R's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
09R Competitors by Total Liabilities
The table below lists competitors of 09R ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aether Holdings, Inc.
NASDAQ:ATHR
|
USA | $637.09K |
|
Appia Energy Corp
OTCQB:APAAF
|
USA | $4.23 Million |
|
Intelligent Protection Management Corp
NASDAQ:IPM
|
USA | $8.47 Million |
|
Gopeng Bhd
KLSE:2135
|
Malaysia | RM244.09 Million |
|
Nigbas Nigde Beton Sanayi ve Ticaret AS
IS:NIBAS
|
Turkey | TL161.14 Million |
|
Eastern Commercial Leasing Public Company Limited
BK:ECL
|
Thailand | ฿3.14 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down 09R's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 09R's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 09R (2021–2024)
The table below shows the annual total liabilities of 09R from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €4.61 Million | -67.23% |
| 2023-12-31 | €14.07 Million | +16.12% |
| 2022-12-31 | €12.12 Million | +203.67% |
| 2021-12-31 | €3.99 Million | -- |